Firma CELLphenomics, Autor bei Presse-Blog

CELLphenomics and Charles River Announce Agreement, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening

8. Januar 20248. Januar 2024 Firma CELLphenomicsForschung und Entwicklungcancer, cdx, cell, cellphenomics, clinical, crl, discovery, new, patients, pd3d, pdx, research, river, sarcomas, with

CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charles River clients with access to CELLphenomics’ proprietary 3D tumor model platform, PD3D®, which will expand Charles River’s 3D in vitro testing services to further optimize Mehr

KYAN Technologies, Alentis Therapeutics, and CELLphenomics Join Forces Combining Cutting-edge Optim.AI™ and PD3D® Models to Advance Claudin-1 Expression Research

29. September 202330. September 2023 Firma CELLphenomicsForschung und Entwicklungalentis, cancer, cell, cellphenomics, clinical, kyan, optimai, pathology, patients, pd3d, pdx, power, project, research, with

KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and organ fibrosis. This partnership aims to accelerate research into Mehr

Berlin scientists use tumor samples drawn from patients with soft tissue sarcomas to individually test their tumor response to ionizing radiation and lay one stepstone towards a translational platform for personalized radiation oncology for rare malignant

26. Juni 202326. Juni 2023 Firma CELLphenomicsForschung und Entwicklungasc, bmc, cancer, cell, cellphenomics, dktk, grade, heidelberg, helios, helmholtz, patients, pd3d, rica, statements, with

Soft tissue sarcomas are a rare group of malignant tumors arising from connective tissue cells, of which more than 70 different subtypes are known to date. The standard therapy for localized, high-grade soft tissue sarcomas is surgery and pre- or Mehr

Bowel cancer: Researchers find possible cause for chemoresistance and partially used patient-derived 3D cell culture models for their studies.

22. Juni 202322. Juni 2023 Firma CELLphenomicsForschung und Entwicklungcancer, cell, cellphenomics, cells, clinical, discovery, imi, MICE, mlu, new, patients, project, research, tumour, with

Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, but they also make it resistant to common forms of chemotherapy. This discovery was made by a research team led by Martin Luther University Halle-Wittenberg (MLU) and Mehr

CELLphenomics’ and KYAN Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry

14. April 2023 Firma CELLphenomicsKooperationen / Fusionenbiomarker, biosimilar, cancer, cell, cellphenomics, clinical, drugs, kyan, los, new, patients, saavedra, treatment, tumor, with

CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach Mehr

European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types

7. September 20228. September 2022 Firma CELLphenomicsForschung und Entwicklunganalytics, cancer, cellphenomics, clinical, discovery, indivumed, indivumeds, indivutype, new, omic, patients, project, research, treatment, with

Indivumed GmbH (“Indivumed”) and CELLphenomics GmbH (“CELLphenomics”) today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating Mehr

Von der Europäischen Union finanziertes Projekt soll zu neuen Therapieansätzen verschiedener solider Tumorarten führen

7. September 20227. September 2022 Firma CELLphenomicsForschung und Entwicklungassays, daten, development, indivumed, indivumeds, indivutype, klinischen, krebsdatenbank, omic, organoid, patienten, präzisionsonkologie, prof, targets, tumoren

Indivumed GmbH („Indivumed“) und CELLphenomics GmbH („CELLphenomics“) geben heute ihre Partnerschaft bekannt, in der eine bisher einzigartige Plattform entsteht, die eine schnellere und effizientere Identifizierung und Validierung therapeutischer Targets ermöglichen wird. Die neue Plattform kombiniert die KI-gestützten onkologischen Analysemethoden von Mehr

Autor: Firma CELLphenomics